 |
|---|
MBF
THERAPEUTICS
™
Next Generation Immunotherapeutics™
MBF Therapeutics is an immunotherapeutic company focused on animal and human health applications of its innovative
T-Max™ immunotherapeutic DNA vaccine platform to create disruptive products for infectious disease and cancer. Initial development is focused on highly efficacious, universal vaccines that prevent significant current and new infectious diseases in livestock and humans.
ABOUT US & OUR ADVANTAGE
SCIENCE & TECHNOLOGY
IN THE PIPELINE
TEAM
PRODUCT
DESCRIPTION
TIMING
MBFT-305
Porcine Respiratory and Reproductive Syndrome vaccines
Research phase
CVXD-001
CaptaVax autogenous vaccines for swine diseases
Clinical trial ongoing, potential sales 2022
MBFT-304
African Swine Fever vaccine
Research phase | Portential approval 2023
COVE-001
Next Generation SARS CoV-2 vaccine for humans
Preclinical studies ongoing | Goal is IND approval 2022
MBFT-202
Canine Multi-tumor sarcoma vaccine
Research phase
LEADERSHIP TEAM
President & Co-Founder
CEO RheoGene; at Rohm and Haas – Bus. Director Biotech, Global Business Manager, Global Business Mgr. Pyridines
THOMAS
TILLETT
PhD - CSO | Co-Founder
Co-founder RheoGene, Immunotope, Rohm & Haas
LORRAINE
KELLER
DVM - CMO
CEO Prairie Diagnostic Services, Intervet, Merial, Baxter, Pfizer
DVM - EVP Business Development
President Novartis AH Vaccines, President Amlan
BOARD OF DIRECTORS
CEO | MBFT
THOMAS
TILLETT
CEO | Biovista
Dr. ARIS
PERSIDIS
former CEO
Marinus Pharmaceuticals
CHRIS
CASHMAN
CEO | Med Aditus
Dr. DHIREN
THAKKER
Watermill Asset Management
CHRIS
BUNGE
Ben Franklin Tech Partners (Board Observer)
TONY
GREEN
COLLABORATIONS & PARTNERSHIPS
MBFT’s business strategy is based upon utilizing collaborations and partnerships to significantly expand our expertise and capabilities. Below is a listing of companies or projects we have announced collaborations or partnerships with, most of these announced in 2020.
OneWorld Biotech – MBFT has a master R&D agreement with this Warminster, Pap-based CRO that works in collaboration with MBFT’s CSO to design and create our products.
Diamond Animal Health – MBFT has a master development agreement with DAH to scale up and manufacture our animal health vaccines for sale and distribution in NAR.
https://www.heska.com/product/manufacturing-services
Smithfield Foods – The largest pork producer in the world is collaborating on th development and testing of innovative vaccines for serious swine infectious diseases in NAR. https://www.mbftherapeutics.com/jan-10-2020
African Swine Fever – MBFT assembled a team of African Swine Fever Virus (ASFV) experts and leading researchers to develop an effective, broad-spectrum ASFV vaccine, leveraging MBF Therapeutics’ proprietary immunotherapy platform and delivery system. The team includes Dr. Bob Rowland (University of Illiniois), Dr. Megan Neiderwerder (Kansas State Univ.), Dr. Luca Popescu (MRI Global), Dr. Tobias Kaeser (NCSU), and Dr. Malla Padidam (OneWorld Biotech)
https://www.mbftherapeutics.com/apr-1-2020
Next-Generation SARS CoV-2 - a collaboration of life science industry experts for the advancement of the next-generation SARS CoV-2 vaccine toward an investigational new drug (IND). The team includes: MRIGlobal – pre-clinical testing, Rymedi – provision of integrated data and diagnostics platform, SSI Strategy – optimized clinical development planning; project management of the IND process, Aldevron– DNA vaccine formulation; scale-up and manufacturing.
https://www.mbftherapeutics.com/july-23-2020
Southwest Research Institute – In-licensed SwRI’s novel calcium phosphate nanoparticle delivery system and collaborating on novel methods to scale up commercial manufacturing and on grant funding opportunities.
